Details for New Drug Application (NDA): 018988
✉ Email this page to a colleague
NDA 018988 describes VASOCIDIN, which is a drug marketed by Novartis and is included in two NDAs. Additional details are available on the VASOCIDIN profile page.
The generic ingredient in VASOCIDIN is prednisolone sodium phosphate; sulfacetamide sodium. There are eighty-eight drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the prednisolone sodium phosphate; sulfacetamide sodium profile page.
The generic ingredient in VASOCIDIN is prednisolone sodium phosphate; sulfacetamide sodium. There are eighty-eight drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the prednisolone sodium phosphate; sulfacetamide sodium profile page.
Summary for 018988
| Tradename: | VASOCIDIN |
| Applicant: | Novartis |
| Ingredient: | prednisolone sodium phosphate; sulfacetamide sodium |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION/DROPS;OPHTHALMIC | Strength | EQ 0.23% PHOSPHATE;10% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Aug 26, 1988 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
